Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2010 2
2011 2
2012 6
2013 11
2014 9
2015 7
2016 3
2017 3
2018 3
2019 3
2020 4
2022 4
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Regional Nodal Irradiation in Early-Stage Breast Cancer.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Whelan TJ, et al. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340. N Engl J Med. 2015. PMID: 26200977 Free PMC article. Clinical Trial.
Achieving molecular diagnostics for Lyme disease.
Eshoo MW, Schutzer SE, Crowder CD, Carolan HE, Ecker DJ. Eshoo MW, et al. Among authors: carolan he. Expert Rev Mol Diagn. 2013 Nov;13(8):875-83. doi: 10.1586/14737159.2013.850418. Expert Rev Mol Diagn. 2013. PMID: 24151851 Review.
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S. Olson R, et al. Among authors: carolan h. JAMA Oncol. 2022 Nov 1;8(11):1644-1650. doi: 10.1001/jamaoncol.2022.4394. JAMA Oncol. 2022. PMID: 36173619 Free PMC article.
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R, Mou B, Baker S, Chng N, Arbour G, Bergman A, Liu M, Schellenberg D, Matthews Q, Huang V, Mestrovic A, Hyde D, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Jiang W, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson RA. Eufemon Cereno R, et al. Among authors: carolan h. Radiother Oncol. 2023 May;182:109576. doi: 10.1016/j.radonc.2023.109576. Epub 2023 Feb 22. Radiother Oncol. 2023. PMID: 36822355 Clinical Trial.
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R, Abraham H, Leclerc C, Benny A, Baker S, Matthews Q, Chng N, Bergman A, Mou B, Dunne EM, Schellenberg D, Jiang W, Chan E, Atrchian S, Lefresne S, Carolan H, Valev B, Tyldesley S, Bang A, Berrang T, Clark H, Hsu F, Louie AV, Warner A, Palma DA, Howell D, Barry A, Dawson L, Grendarova P, Walker D, Sinha R, Tsai J, Bahig H, Thibault I, Koul R, Senthi S, Phillips I, Grose D, Kelly P, Armstrong J, McDermott R, Johnstone C, Vasan S, Aherne N, Harrow S, Liu M. Olson R, et al. Among authors: carolan h. BMC Cancer. 2024 Feb 3;24(1):171. doi: 10.1186/s12885-024-11905-7. BMC Cancer. 2024. PMID: 38310262 Free PMC article.
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
Baker S, Lechner L, Liu M, Chang JS, Cruz-Lim EM, Mou B, Jiang W, Bergman A, Schellenberg D, Alexander A, Berrang T, Bang A, Chng N, Matthews Q, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Arbour G, Yu I, Tyldesley S, Olson RA. Baker S, et al. Among authors: carolan h. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1497-1506. doi: 10.1016/j.ijrobp.2024.01.008. Epub 2024 Jan 12. Int J Radiat Oncol Biol Phys. 2024. PMID: 38220069 Clinical Trial.
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial.
Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, Olson RA. Baker S, et al. Among authors: carolan h. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):617-626. doi: 10.1016/j.ijrobp.2022.05.033. Epub 2022 Jun 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 35667528 Clinical Trial.
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial.
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA. Baker S, et al. Among authors: carolan h. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):856-861. doi: 10.1016/j.ijrobp.2022.06.094. Epub 2022 Jul 13. Int J Radiat Oncol Biol Phys. 2022. PMID: 35840110 Clinical Trial.
55 results